GCV Toxicity Curve for NIT-1 Cells




FIG. 1A




FIG. 1B

"Promoter Driven Tissue Specific Cytotoxic Agents and Methods of Use" Inventors: F. Charles Brunicardi, Ph.D. Atty.: Tamsen Valoir, Ph.D. (713) 951-3381 Atty. Docket No.: 60710-00002USC1

2/9





FIG. 2








FIG. 4








FIG. 5C

"Promoter Driven Tissue Specific Cytotoxic Agents and Methods of Use" Inventors: F. Charles Brunicardi, Ph.D. Atty.: Tamsen Valoir, Ph.D. (713) 951-3381 Atty. Docket No.: 60710-00002USC!

6/9




FIG. 6A




FIG. 6B

Insulin Secretion SSTR-5-KO




FIG. 7

8/9




FIG. 8


"Promoter Driven Tissue Specific Cytotoxic Agents and Methods of Use" Inventors: F. Charles Brunicardi, Ph.D. Atty.: Tamsen Valoir, Ph.D. (713) 951-3381 Atty. Docket No.: 60710-00002USC1

9/9





Percent Cell Survival F9



p<0.05 via student t-test, n=48 per construct

FIG. 9